Home›Screener›VERV›Profile
C
55/100

Verve Therapeutics

VERVCardiovascular
← Signals View
Analyst Summary
✓ VERIFIED2026-04-11

Verve Therapeutics (VERV) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 1[1].

No Form 4 insider filings for VERV were recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR (2026-04-11) ↗
Clinical Trials
3
NCT06112327Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSign profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-202026-07-17
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Cardiovascular)
CYTKCytokinetics Inc
C
BEATHeartbeam, Inc.
D
ESPREsperion Therapeutics
F
CDIOCardio Diagnostics Holdings Inc.
F
HTFLHeartflow, Inc.
F
Data Provenance
clinical trial3 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR